Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling

Huan Liu, Abudureyimujiang Aili, Zheng Kuang, Liting Cao, Zemin Li, Ying Shang, Yingying Ge, Tao Hu, Yongchang Sun, Wei Zhao, Rong Jin, Chun ChangAdvanced 2026 · DOI

TL;DR

Researchers have identified a specific ceramide, Cer24:1, that is deficient in severe neutrophilic asthma. Supplementing Cer24:1 in mouse models reduced airway inflammation by targeting the EP2 receptor on T cells, suppressing a key signaling pathway that drives this severe asthma subtype. This discovery offers a potential new therapeutic avenue for steroid-resistant asthma.

What Problem Does This Paper Address?

Severe asthma, particularly the neutrophilic asthma (NA) subtype, is a significant clinical challenge. NA is characterized by inflammation driven by Th17 cells and is often resistant to standard steroid treatments. While lipid mediators are known to influence inflammation, the specific lipids involved in the Th17-neutrophil axis in NA have remained elusive. This paper aims to identify these key lipid mediators and understand their role in NA pathogenesis, with the ultimate goal of finding new therapeutic targets.

Methods

The study employed a multi-pronged approach:

  • Integrated Lipidomic Profiling: They analyzed exhaled breath condensate, plasma, and sputum from NA patients and a mouse model of Th17-driven airway inflammation to identify altered lipid species.
  • In Vivo Studies: They used mouse models of NA, including those with impaired ceramide generation (Smpd1 knockout mice) and tested the therapeutic effects of Cer24:1 supplementation.
  • Molecular Docking and Binding Assays: Structure-guided molecular docking, surface plasmon resonance (SPR), and biotin-ceramide pull-down assays were used to investigate the direct interaction of Cer24:1 with potential cellular targets.
  • Functional Assays: In vitro and in vivo experiments assessed the impact of Cer24:1 on Th17 cell differentiation, cytokine production, and inflammatory responses.
  • Signaling Pathway Analysis: Western blotting and phosphoproteomic analysis were used to elucidate the downstream signaling pathways affected by Cer24:1.

Datasets

  • Clinical Samples: Exhaled breath condensate (EBC), plasma, and induced sputum from a cohort of 173 asthma patients and 53 healthy controls.
  • Murine Models:
    • A mouse model of NA induced by house dust mite (HDM) and lipopolysaccharide (LPS).
  • Smpd1 knockout mice (Smpd1-/-) to study the role of ceramide generation.
  • Single-cell RNA sequencing datasets: Publicly available datasets (GSE135779, GSE142637, and GSE162577) were analyzed to identify GPCRs expressed on CD4+ T cells.

Key Insights and Ideas

  • Ceramide 24:1 as a Key Player: The study pinpoints Cer24:1, a very-long-chain ceramide, as a critical lipid mediator in NA. Its deficiency is strongly associated with disease severity and Th17-driven inflammation.
  • EP2 Receptor as the Target: Cer24:1 doesn't just float around; it directly binds to the prostaglandin E2 receptor EP2 on CD4+ T cells. This is a significant finding, linking ceramide metabolism to prostaglandin signaling.
  • JAK2-STAT3 Pathway Inhibition: The interaction of Cer24:1 with EP2 leads to the suppression of the JAK2-STAT3 signaling pathway, which is crucial for Th17 cell differentiation. This provides a clear mechanistic link.
  • Competitive Inhibition by PGE2: The fact that PGE2 (a known EP2 ligand) can reverse Cer24:1's protective effects highlights the competitive nature of their interaction at the EP2 receptor and underscores the importance of the ceramide-PGE2 balance.
  • Therapeutic Potential: The successful alleviation of NA symptoms in mouse models by Cer24:1 supplementation suggests a promising new therapeutic strategy for this difficult-to-treat asthma subtype.

Key Results

  • Cer24:1 Deficiency in NA: NA patients showed significantly reduced levels of Cer24:1 in EBC, plasma, and sputum compared to healthy controls and non-NA asthma patients.
  • Correlation with Disease Severity: Lower Cer24:1 levels correlated with increased asthma severity, higher Th17 cell proportions, and more neutrophils in sputum.
  • Therapeutic Efficacy of Cer24:1: In HDM/LPS-induced NA mice, Cer24:1 treatment reduced airway hyperresponsiveness, IL-17A levels, and neutrophil infiltration. It also decreased the proportion of Th17 cells in the lungs.
  • Smpd1 Knockout Exacerbates NA: Mice lacking Smpd1 (and thus impaired ceramide generation) showed exacerbated Th17-dominated inflammation upon HDM/LPS challenge.
  • Cer24:1 Selectively Inhibits Th17 Differentiation: In vitro, Cer24:1 dose-dependently inhibited the differentiation of pathogenic and nonpathogenic Th17 cells, but not Th1, Th2, or iTreg cells.
  • EP2-STAT3 Axis Modulation: Cer24:1 was shown to directly bind EP2, suppress JAK2-STAT3 phosphorylation, and downregulate RORγt expression, key factors in Th17 differentiation.
  • PGE2 Reversal of Effects: Exogenous PGE2 administration reversed the anti-inflammatory effects of Cer24:1 in NA mouse models, including increased Th17 cell numbers and STAT3 phosphorylation.

Limitations and Future Work

  • Clinical Translation: While promising, the findings are primarily from preclinical models. Further studies are needed to confirm the therapeutic efficacy and safety of Cer24:1 in human clinical trials.
  • Specificity of Ceramide Binding: The study focused on Cer24:1. While other VLC-ceramides showed similar trends, the precise role and specificity of other ceramide species in NA warrant further investigation.
  • Broader Impact of Ceramide Metabolism: The study highlights the importance of ceramide metabolism in asthma. Future work could explore how other aspects of sphingolipid metabolism might be modulated for therapeutic benefit.
  • Mechanisms of PGE2 Interaction: While competitive binding to EP2 is demonstrated, a deeper understanding of the downstream consequences of this interaction and how it influences the overall immune response could be explored.
  • Longitudinal Studies: The authors suggest that longitudinal studies are needed to understand how ceramide levels fluctuate across disease stages and during exacerbations.

Summary updated

Abstract

Dysregulated chronic inflammation underlies a spectrum of severe asthma phenotypes, among which neutrophilic asthma (NA) represents a treatment-recalcitrant endotype characterized by Th17-driven airway inflammation and steroid resistance. Although lipid mediators are known to play dual roles in promoting and resolving inflammation, the lipid species governing the Th17-neutrophil axis in NA remain unknown. Here, through integrated lipidomic profiling of clinical samples (exhaled breath condensate, plasma, sputum) from an NA cohort and a murine model of Th17-driven airway inflammation, a deficiency in very-long-chain ceramides, notably Cer24:1, was identified. This reduction correlated with disease severity and neutrophilic inflammation. In vivo, Cer24:1 supplementation alleviated airway hyperresponsiveness and neutrophilic infiltration, while Smpd1 knockout mice-with impaired ceramide generation-displayed exacerbated Th17 pathology. Using structure-guided molecular docking, surface plasmon resonance, and functional assays, Cer24:1 was shown to directly target the prostaglandin E2 receptor EP2 on CD4<sup>+</sup> T cells. This interaction suppressed JAK2-STAT3 signaling and RORγt-driven Th17 differentiation. Notably, PGE<sub>2</sub> competitively reversed Cer24:1's protective effects, further supporting EP2-dependent modulation. Our results reveal Cer24:1 as an endogenous pro-resolving lipid that constrains neutrophilic inflammation via direct modulation of the EP2-STAT3 axis in Th17 cells, providing a new metabolic checkpoint and potential therapeutic strategy for severe neutrophilic asthma.
BibTeX
@inproceedings{liu2026endogenous,
  author = {Huan Liu and Abudureyimujiang Aili and Zheng Kuang and Liting Cao and Zemin Li and Ying Shang and Yingying Ge and Tao Hu and Yongchang Sun and Wei Zhao and Rong Jin and Chun Chang},
  title = {{Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling}},
  booktitle = {Advanced},
  year = {2026},
  doi = {10.1002/advs.202520695},
}
Figure